{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:18:11Z","timestamp":1778872691463,"version":"3.51.4"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0213774","type":"journal-article","created":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T14:13:48Z","timestamp":1552659228000},"page":"e0213774","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":20,"title":["An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism"],"prefix":"10.1371","volume":"14","author":[{"given":"Geoffrey A.","family":"Block","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn M.","family":"Chertow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John T.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjie","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2039-2545","authenticated-orcid":true,"given":"Omar","family":"Mather","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Tomlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Serenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,3,15]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.ki.5002287","article-title":"Development and progression of secondary hyperparathyroidism in chronic kidney disease: Lessons from molecular genetics","volume":"74","author":"WG Goodman","year":"2008","journal-title":"Kidney Int"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"17088","DOI":"10.1038\/nrdp.2017.88","article-title":"Chronic kidney disease","volume":"3","author":"P Romagnani","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"A Levin","year":"2007","journal-title":"Kidney Int"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"J Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10041","key":"ref5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(16)30508-6","article-title":"The heart and vascular system in dialysis","volume":"388","author":"C Wanner","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.113.204834","article-title":"Pharmacology of AMG 416 (velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients","volume":"346","author":"S Walter","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"ref7","unstructured":"Parsabiv [package insert]. Thousand Oaks, CA: Amgen Inc.; 2017"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: A randomized clinical trial","volume":"317","author":"GA Block","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2016.19456","article-title":"Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials","volume":"317","author":"GA Block","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ki.2013.289","article-title":"AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients","volume":"85","author":"KJ Martin","year":"2014","journal-title":"Kidney Int"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"J Cunningham","year":"2005","journal-title":"Kidney Int"},{"issue":"26","key":"ref12","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"GM Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"KDIGO Workgroup. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD) 2017 [cited 2018 January 31]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/kdigo.org\/wp-content\/uploads\/2017\/02\/2017-KDIGO-CKD-MBD-GL-Update.pdf\" xlink:type=\"simple\">http:\/\/kdigo.org\/wp-content\/uploads\/2017\/02\/2017-KDIGO-CKD-MBD-GL-Update.pdf<\/ext-link>.","DOI":"10.22141\/2307-1257.6.3.2017.109030"},{"key":"ref14","unstructured":"Center for Drug Evaluation and Research. Summary review of class 2 resubmission 2017 [cited 2018 January 31]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208325Orig1s000SumR.pdf\" xlink:type=\"simple\">https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208325Orig1s000SumR.pdf<\/ext-link>."},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2014040414","article-title":"Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial","volume":"26","author":"SM Moe","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jim.2017.03.005","article-title":"Clinical immunogenicity of the D-amino acid peptide therapeutic etelcalcetide: method development challenges and anti-drug antibody clinical impact assessments","volume":"445","author":"MA Kroenke","year":"2017","journal-title":"J Immunol Methods"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1067\/mpd.2000.103447","article-title":"Corrected QT interval (QTc) prolongation and syncope associated with pseudohypoparathyroidism and hypocalcemia","volume":"136","author":"TC Huang","year":"2000","journal-title":"J Pediatr"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0022-0736(89)90026-5","article-title":"Hypocalcemic Torsades de Pointes","volume":"22","author":"T Akiyama","year":"1989","journal-title":"J Electrocardiol"},{"key":"ref19","unstructured":"Amgen Inc. Swiss summary of the risk management plan (RMP) for Parsabiv (etelcalcetide), Zug, Switzerland. 2017 [cited 2018 February 22]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/\u2026\/WC500217125.pdf\" xlink:type=\"simple\">www.ema.europa.eu\/docs\/en_GB\/document_library\/\u2026\/WC500217125.pdf<\/ext-link>."},{"issue":"10","key":"ref20","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/pds.3845","article-title":"Management of serum calcium reductions among patients on hemodialysis following cinacalcet initiation","volume":"24","author":"SM Brunelli","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/1091581816633407","article-title":"Nonclinical safety profile of etelcalcetide, a novel peptide calcimimetic for the treatment of secondary hyperparathyroidism","volume":"35","author":"MR Fielden","year":"2016","journal-title":"Int J Toxicol"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40262-016-0433-0","article-title":"Pharmacokinetics, biotransformation, and excretion of [14C]etelcalcetide (AMG 416) following a single microtracer intravenous dose in patients with chronic kidney disease on hemodialysis","volume":"56","author":"R Subramanian","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ki.2014.349","article-title":"Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism","volume":"87","author":"GJ Behets","year":"2015","journal-title":"Kidney Int"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/ki.1995.22","article-title":"Clinical and echocardiographic disease in patients starting end-stage renal disease therapy","volume":"47","author":"RN Foley","year":"1995","journal-title":"Kidney Int"},{"key":"ref25","unstructured":"Sensipar [package insert]. Thousand Oaks, CA: Amgen Inc.; 2017"},{"issue":"8","key":"ref26","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1124\/dmd.115.068007","article-title":"Nonclinical pharmacokinetics disposition, and drug-drug interaction potential of a novel D-amino acid peptide agonist of the calcium sensing receptor AMG 416 (etelcalcetide)","volume":"44","author":"R Subramanian","year":"2016","journal-title":"Drug Metab Dispos"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0213774","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T06:23:48Z","timestamp":1589005428000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0213774"}},"subtitle":[],"editor":[{"given":"Mario","family":"Cozzolino","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,3,15]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0213774","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735332563.793577512","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,15]]}}}